Summit Therapeutics Completes Enrollment of Phase 2 Trial

Summit Therapeutics Completes Enrollment of Phase 2 Trial

Summit Therapeutics (SMMT) said Monday it has completed enrollment in PhaseOut DMD, a phase 2 proof of concept clinical trial of the utrophin modulator, ezutromid, in patients with Duchenne muscular dystrophy (DMD). The study aims to provide proof of concept for ezutromid through measures of a number of endpoints related to muscle structure, health and function. The Company believes the trial could provide valuable insight into utrophin modulation as a […]

Read More ˃
Vascular Biogenics Reports Positive Data

Vascular Biogenics Reports Positive Data

Biopharmaceutical company Vascular Biogenics reported pre-clinical data indicating that treatment with ofranergene obadenovec (VB-111) augments the anti-tumor activity of a PD-L1 blocker in lung cancer and melanoma models. The company said data show that treatment with either VB-111 or anti-PD-L1 reduced tumor burden in mice induced with Lewis lung carcinoma (LLC), by 42% and 51% versus saline control, respectively. However, the combination of both agents resulted in an amplified effect, […]

Read More ˃
MidEast Shares Mixed

MidEast Shares Mixed

Middle East stocks were mixed, finding support from better-than-expected corporate results. Jarir said Q1 profit jumped 26.5% from the year-ago level and topped expectations. Sales gained 20.3% from last year. Its board also recommended distributing 2.2 riyals per share for the period, higher than the 1.75 riyals it paid out in the prior year period. Al Othaim said net profit gained 29% from last year and sales gained. Dubai Financial […]

Read More ˃
Unisys Lands Task Order from IRS

Unisys Lands Task Order from IRS

Unisys said early Tuesday it has been selected by the U.S. Internal Revenue Service (IRS) to continue its work updating, operating and maintaining the system used by the U.S. government to verify and monitor excise fuel tax filings, the company said Tuesday. The IRS selected Unisys for this work through a competitive task order awarded under the Total Information Processing Support Services-4 contract. The task order has a one-year base […]

Read More ˃
Bristol-Myers Squibb Receives China FDA Approval

Bristol-Myers Squibb Receives China FDA Approval

Shares of Bristol-Myers Squibb were up less than 1% pre-market Friday after the drugmaker said that the China Food and Drug Administration approved a regimen comprised of the company’s Daklinza (daclatasvir) and Sunvepra (asunaprevir) to treat patients infected with genotype 1b chronic hepatitis C virus (HCV). Daklinza has also been approved in China for combination use with other agents, including sofosbuvir, for adult patients with HCV genotypes 1-6 infection.

Read More ˃
CenturyLink’s Subsidiary Qwest Agrees To Sell Debt Securities

CenturyLink’s Subsidiary Qwest Agrees To Sell Debt Securities

CenturyLink said Wednesday that its wholly-owned subsidiary, Qwest Corporation has agreed to sell $575 million aggregate principal amount of 6.75% notes due 2057. Qwest also granted the underwriters of this offering an option to acquire up to an additional $86.25 million principal amount of these notes to cover any over-allotments. The closing of this offering is expected to occur on April 27, subject to customary closing conditions. Qwest said it […]

Read More ˃
Energy Stocks Jumping Out to Big Gains in Market Surge

Energy Stocks Jumping Out to Big Gains in Market Surge

Energy stocks were sharply higher, with the NYSE Energy Sector Index climbing over 1.9% while shares of energy companies in the S&P 500 were up nearly 2.2% as a group. Crude oil for April delivery was down 10 cents at $53.91 per barrel while April natural gas futures were a penny higher at $2.79 per 1 million BTU. In company news, Kinder Morgan (KMI) was trending higher in mid-day trading […]

Read More ˃